Critique Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indicator: Together with chemotherapy, with the treatment of Grownup patients with locally recurrent unresectable or metastatic triple-unfavorable breast cancer that have not acquired prior chemotherapy for metastatic ailment and whose tumours Convey programmed mobile Loss of life-ligand 1 (mixed optimistic score ≥ ten) as https://thomask349tnn6.wannawiki.com/user